Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
BIIB News
The quest to treat Alzheimer's disease is heating up as drugmakers Eli Lilly (LLY), Biogen (BIIB) and Roche (RHHBY) blaze new trails. But there are speed bumps...
Biogen BIIB and partner Eisai recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delayed th...
BASEL, Switzerland, March 26, 2024--(BUSINESS WIRE)--Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with B...
Analyst ratings
74%
of 35 ratingsMore BIIB News
Biogen Inc. (BIIB) closed at $216.69 in the latest trading session, marking a -0.65% move from the prior day. This change lagged the S&P 500's daily loss of 0.3...
Loading... Loading... During the last three months, 18 analysts shared their evaluations of Biogen BIIB, revealing diverse outlooks from bullish to bearish. T...
Laboratory Corporation of America Holdings, Inc. or Labcorp LH recently launched a new blood test that detects phosphorylated tau 217 (pTau217) — a biomarker fo...
Biogen (BIIB) noted that Eisai (ESAIY) announced an update on the regulatory review process of lecanemab by the European Medicines Agency, or EMA. Eisai announc...
(Rewrites with comment from Eisai, adds background in paragraph 6, comment from EMA in paragraph 5) March 22 (Reuters) - The European Union's medicines regulat...